Cells, Proteins and Bioprocessing


Tuesday, 17 June 2014 09:30 – Thursday, 19 June 2014 17:00

Cineworld: The O2
Peninsula Square
SE10 0DX
United Kingdom

This three day event will discuss three main topics

  • Cell Culture Technology Event: Recent advances, future prospect
  • Therapeutic proteins and antibodies: from design to function
  • Bioprocess development: Discussing facilitation of industrial uptake

With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking.

This event  has CPD accreditation

Who Should Attend
All academic and biotechnology/biopharma professionals interested in biological protein and antibody engineering, functional and potency evaluations, biological therapeutics mechanisms of action and translational implications for therapy would find this meeting useful.  Individuals interested in the any process that uses complete living cells or their components (e.g., bacteriaenzymeschloroplasts) to obtain desired products should also attend this event.

The deadline for abstract submissions for oral presentation is April 10th 2014.Abstracts for poster presentation only can be submitted up to two weeks before the event.

You can download the instructions for authors at

There will be an open poster session, where posters can be submitted on any subject related to Cells, Proteins and Bioprocessing

Program Outline

Day 1:  Cell Culture Technology Event: Recent advances, future prospect 

Cell culture has matured to become the pivotal technology in biopharmaceutical research, development and production, and its use in this and other areas continues to expand rapidly. In vitro models are replacing animals in many tests and assays; its enormous potential in the fields of stem cell and regenerative medicine has hardly started to be realized; its utility in research grows ever faster.

This session will examine some of the latest applications of cell culture technology, some that are still “over the horizon”, and some of the problems that must be solved before it can reach its full potential.

Day 2:  Therapeutic proteins and antibodies: from design to function
This session discusses new developments in therapeutic protein and antibody engineering with specific focus on science and technology of modifying proteins and antibodies (and the conditions of their manufacture) toward specific predefined properties that allow them to act as effective biological drugs. Special emphasis will be placed on structure-function relationships, mechanisms of action, potency and efficacy in disease-relevant models and in clinical trials. There will be plenty of opportunity for discussion and debate addressing the wide range of disciplines applied to the rapid and economical production of these molecules for biological therapies
Day 3:  Bioprocess development: Discussing facilitation of industrial uptake.

This will focus on recent technologies used in high throughput bioprocess development, from clone selection through to analysis of final product and formulation.   Bioprocess miniaturization, effective upscaling, downstream processing and analytics will all be discussed.  Expert speakers will describe the development and use of current technologies together with the  technical and regulatory hurdles that must be overcome to facilitate wider industrial uptake.

Talks Include:

Micro-cariers: its role in reducing the cost, time, and efforts towards industrial cells proliferation and protein productions

Dr Ali Hilal-Alnaqbi, Assistant Professor UAEU, Visiting Assistant Professor, Harvard, USA

Therapeutic IgE antibodies: enhanced effector functions for cancer therapy

Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London School of Medicine, UK

Introducing a Novel liquid 3 Dimensional Scaffold for Culturing Cells in 3D

Dr Anthony Mitchell Davies, Director of INCHSA, Dept Clinical Medicine Trinity College Dublin, Ireland

Quantum dot- conjugated antibodies as diagnostic and therapeutic tools for cancer imaging and treatment
Dr Weiming Xu, CEO, London Biotech Ltd, UK

Real time, label-free characterisation of live cells in monolayer culture using high resolution, multi-modal light microscopy

Dr Melissa Mather, Principal Research Fellow, Institute of Biophysics, Imaging and Optical Science, University of Nottingham, UK

Biofabrication technologies for 3D cell culture systems
Dr Lorenzo Moroni, Associate Professor, University of Twente, Tissue Regeneration Department, The Netherlands

Selection of isotype for immunomodulatory anti-cancer antibodies

Dr Ann White, Senior Research Fellow, University of Southampton, UK

3D-tetraculture system mimicking the cellular organization at the alveolar barrier.
Dr Arno C. Gutleb, Chef de projet, Centre de Recherche Public – Gabriel Lippmann, Luxembourg

Additional Speakers Include

  • Professor. Fuad Fares, University of Haifa, Israel
  • Dr Sergio A. Quezada, Immune Regulation and Tumour Immunotherapy Group, UCL Cancer Institute, UK
  • Dr Miriam Dwek, University of Westminster, UK

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: